Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Ancylostoma brasiliense, a species of hookworm, has been investigated as part of the broader field of helminth therapy for treating immune-mediated diseases, including colitis (inflammatory bowel disease). The scientific rationale stems from the "hygiene hypothesis" and observations that parasitic infections may modulate the host immune system, reducing inflammation. Animal studies, particularly in mice, have shown that infection with hookworms or administration of their antigens can ameliorate colitis symptoms by shifting immune responses from pro-inflammatory (Th1/Th17) to regulatory (Treg/Th2) profiles. Several preclinical studies have used Ancylostoma brasiliense specifically to induce mild, controlled infections in mice and have reported reductions in colitis severity, improved histology, and changes in cytokine profiles suggestive of immune modulation.

However, clinical evidence in humans is limited, and most human studies have used other helminth species, such as Necator americanus or Trichuris suis. There are no large-scale clinical trials using Ancylostoma brasiliense in human colitis patients. Concerns remain about safety, dosing, and long-term effects. Therefore, while preclinical data support the potential of Ancylostoma brasiliense or its products in modulating colitis, robust human evidence is lacking, and use remains experimental.

More about Ancylostoma brasiliense
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Ancylostoma brasiliense

Products containing Ancylostoma brasiliense